Dermira (DERM) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 22, 2023 4:01 PM EDTAchieved Last Patient Out milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
Company to hold conference call on May 22, 2023, at 4:30 p.m. ET
SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (Journey Medical or the Company), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate... More
